ERBB2 and breast cancer: Randomized controlled trials such as NeoSphere, PEONY and NeoALLTO have confirmed the efficacy of NAT based on trastuzumab in combination with pertuzumab + cytotoxic drugs for patients with HER2-positive BC (4–6).